Persistence of Antibodies to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: 1-Year Follow-up With Memory Probe Vaccination
Robert L. Atmar(Baylor College of Medicine), John J. Treanor(University of Rochester Medicine), Jeffrey B. Rosen(Target (United States)), Matthew Davis, Laurence Chu, Paul M. Mendelman(Takeda (Switzerland)), Donald M. Brandon(SUNY Upstate Medical University), Sharon E. Frey(St. Louis VA Medical Center), Astrid Borkowski(Takeda (Switzerland)), James Sherwood(Takeda (Switzerland)), David L. Bernstein(Drexel University), Eric Lloyd(Takeda (United States)), R. Epstein, Frank Baehner(Takeda (Switzerland)), Mohamed Al‐Ibrahim, Jakob P. Cramer(Universität Hamburg)
Cited by 30
Related Papers
Epidemic Profile of Shiga-Toxin–Producing<i>Escherichia coli</i>O104:H4 Outbreak in Germany
|New England Journal of Medicine|2011|1.1k
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
|New England Journal of Medicine|2021|937
Travel-associated infection presenting in Europe (2008–12): an analysis of EuroTravNet longitudinal, surveillance data, and evaluation of the effect of the pre-travel consultation
|The Lancet Infectious Diseases|2014|248
Adjuvanted Intranasal Norwalk Virus‐Like Particle Vaccine Elicits Antibodies and Antibody‐Secreting Cells That Express Homing Receptors for Mucosal and Peripheral Lymphoid Tissues
|The Journal of Infectious Diseases|2010|227
Severe Monkeypox in Hospitalized Patients — United States, August 10–October 10, 2022
|MMWR Morbidity and Mortality Weekly Report|2022|204